[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68, 394−424. doi:  10.3322/caac.21492
[2] Conticchio M, Inchingolo R, Delvecchio A, et al. Radiofrequency ablation vs surgical resection in elderly patients with hepatocellular carcinoma in Milan criteria. World J Gastroenterol, 2021; 27, 2205−18. doi:  10.3748/wjg.v27.i18.2205
[3] Qin SK, Li Q, Gu SZ, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol, 2021; 6, 559−68. doi:  10.1016/S2468-1253(21)00109-6
[4] Dixon SJ, Lemberg K, Lamprecht M, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 2012; 149, 1060−72. doi:  10.1016/j.cell.2012.03.042
[5] Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ, 2018; 25, 486−541. doi:  10.1038/s41418-017-0012-4
[6] Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med, 2019; 133, 130−43. doi:  10.1016/j.freeradbiomed.2018.09.043
[7] Liu YQ, Gu W. The complexity of p53-mediated metabolic regulation in tumor suppression. Semin Cancer Biol, 2022; 85, 4−32. doi:  10.1016/j.semcancer.2021.03.010
[8] Yang ZH, Song YS, Li Y, et al. Integrative analyses of prognosis, tumor immunity, and ceRNA network of the ferroptosis-associated gene FANCD2 in hepatocellular carcinoma. Front Genet, 2022; 13, 955225. doi:  10.3389/fgene.2022.955225
[9] Navarro C, Ortega Á, Santeliz R, et al. Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches. Pharmaceutics, 2022; 14, 1303. doi:  10.3390/pharmaceutics14061303
[10] Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017; 547, 453−7. doi:  10.1038/nature23007
[11] Chen ML, Shi ZH, Sun YQ, et al. Prospects for anti-tumor mechanism and potential clinical application based on glutathione peroxidase 4 mediated ferroptosis. Int J Mol Sci, 2023; 24, 1607. doi:  10.3390/ijms24021607
[12] Wang WM, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature, 2019; 569, 270−4. doi:  10.1038/s41586-019-1170-y
[13] Friedmann Angeli JP, Krysko DV, Conrad M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat Rev Cancer, 2019; 19, 405−14. doi:  10.1038/s41568-019-0149-1
[14] Jiang P, Gu SQ, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med, 2018; 24, 1550−58. doi:  10.1038/s41591-018-0136-1
[15] Ye CY, Lu YE, Yuan ZJ, et al. Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma. Front Genet, 2022; 13, 922914. doi:  10.3389/fgene.2022.922914
[16] Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol, 2018; 29, 71−83.
[17] Lee YH, Tai D, Yip C, et al. Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front Immunol, 2020; 11, 568759. doi:  10.3389/fimmu.2020.568759
[18] Tai D, Choo SP, Chew V. Rationale of immunotherapy in hepatocellular carcinoma and its potential biomarkers. Cancers (Basel), 2019; 11, 1926. doi:  10.3390/cancers11121926
[19] Wang QH, Li ML, Yang M, et al. Analysis of immune-related signatures of lung adenocarcinoma identified two distinct subtypes: implications for immune checkpoint blockade therapy. Aging (Albany NY), 2020; 12, 3312−39.
[20] Zhou J, Sun HC, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer, 2020; 9, 682−720. doi:  10.1159/000509424
[21] Stockwell BR, Jiang XJ, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol, 2020; 30, 478−90. doi:  10.1016/j.tcb.2020.02.009
[22] Komatsu H, Masuda T, Iguchi T, et al. Clinical significance of FANCD2 gene expression and its association with tumor progression in hepatocellular carcinoma. Anticancer Res, 2017; 37, 1083−90. doi:  10.21873/anticanres.11420
[23] Chen ZY, Yu HT, Wu LJ, et al. Identification and validation of hub genes predicting prognosis of hepatocellular carcinoma. Dig Surg, 2022; 39, 24−31. doi:  10.1159/000520893
[24] Zou YL, Palte MJ, Deik AA, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun, 2019; 10, 1617. doi:  10.1038/s41467-019-09277-9
[25] Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev, 2021; 92, 102134. doi:  10.1016/j.ctrv.2020.102134
[26] Jácome AA, Castro ACG, Vasconcelos JPS, et al. Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: a meta-analysis. JAMA Netw Open, 2021; 4, e2136128. doi:  10.1001/jamanetworkopen.2021.36128
[27] Liu ZQ, Liu L, Guo CG, et al. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. Int Immunopharmacol, 2021; 101, 108340. doi:  10.1016/j.intimp.2021.108340
[28] Giuffrida P, Arpa G, Grillo F, et al. PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability. Mod Pathol, 2020; 33, 1398−409. doi:  10.1038/s41379-020-0497-0
[29] Eso Y, Shimizu T, Takeda H, et al. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol, 2020; 55, 15−26. doi:  10.1007/s00535-019-01620-7
[30] Xiao J, Li WY, Huang Y, et al. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer, 2021; 21, 282. doi:  10.1186/s12885-021-07942-1
[31] Hirsch D, Gaiser T, Merx K, et al. Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. J Cancer Res Clin Oncol, 2021; 147, 263−73. doi:  10.1007/s00432-020-03335-2
[32] Jacob JB, Jacob MK, Parajuli P. Review of immune checkpoint inhibitors in immuno-oncology. Adv Pharmacol, 2021; 91, 111−39.
[33] Feng GS, Hanley KL, Liang Y, et al. Improving the efficacy of liver cancer immunotherapy: the power of combined preclinical and clinical studies. Hepatology, 2021; 73, 104−14.
[34] Lee SK, Lee SW, Jang JW, et al. Immunological markers, prognostic factors and challenges following curative treatments for hepatocellular carcinoma. Int J Mol Sci, 2021; 22, 10271. doi:  10.3390/ijms221910271
[35] Pearlman AH, Hwang MS, Konig MF, et al. Targeting public neoantigens for cancer immunotherapy. Nat Cancer, 2021; 2, 487−97. doi:  10.1038/s43018-021-00210-y
[36] Xu LL, Zou C, Zhang SS, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol, 2022; 15, 87. doi:  10.1186/s13045-022-01307-2